Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$30.07 USD
+0.76 (2.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $30.25 +0.18 (0.60%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum D VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales
- 573.93
- 649.43
- 567.50
- 509.35
- 383.40
- Revenue - Line of Business (LOBR)
- Revenues: Royalty revenues
- 33.59
- 17.81
- 12.27
- 11.05
- 9.36
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: Qelbree
- 140.20
- 61.30
- 9.88
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: GOCOVRI
- 119.60
- 104.40
- 9.78
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: Oxtellar XR
- 113.40
- 115.40
- 110.70
- 98.70
- 88.20
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: Trokendi XR
- 94.30
- 261.20
- 304.80
- 319.60
- 295.20
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: APOKYN
- 75.10
- 75.30
- 99.23
- 74.30
- --
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales: Other
- 31.30
- 31.80
- 33.09
- 16.69
- --